Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Novo Nordisk will pay $1.8 billion to acquire Emisphere Technology, a US firm with technology for creating oral versions of biologic drugs that otherwise would have to be injected. Novo licenses the technology to formulate semaglutide, a diabetes drug it sells as Rybelsus. Emisphere’s technology is based on carriers, such as salcaprozate sodium, that enhance absorption of both small and large molecules.
This article has been sent to the following recipient: